Keywords: داروهای یتیم; Pulmonary arterial hypertension; Orphan drug; Rare disease; Drug evaluation;
مقالات ISI داروهای یتیم (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: داروهای یتیم; botulism; cost-effectiveness; efficacy; human botulism immune globulin; infant botulism; orphan disease; orphan drug; rare diseases; BIG-IV; Human Botulism Immune Globulin Intravenous; CDPH; California Department of Public Health; FDA; US Food and Drug Ad
Keywords: داروهای یتیم; Adversity; Biopharmaceuticals; Bispecifics; Cytokine release; Emerging therapies; Gene and cell therapies; Gene editing; Immune-oncology; Immunomodulation; Microbiome; Minimum anticipated biological effect level (MABEL); Monoclonal antibodies; No observed
Keywords: داروهای یتیم; Eroom's law; innovation; drug approval; CVD; cardiovascular disease; FDA; Food and Drug Administration; NIH; National Institutes of Health; OD; orphan drug; PPMD; parent project muscular dystrophy; RCT; randomized controlled trials; R&D; research and de
Keywords: داروهای یتیم; big data; drug safety; orphan drug; pharmacovigilance; rare disease; social media;
Keywords: داروهای یتیم; corporate venture; intellectual property; open innovation; orphan drug; specialty pharma
Enzyme replacement therapy in perinatal hypophosphatasia: Case report of a negative outcome and lessons for clinical practice
Keywords: داروهای یتیم; Hypophosphatasia; Alkaline phosphatase; ALPL; Skeletal dysplasia; Enzyme replacement therapy; Asfotase alfa; Orphan drug;
Original ArticleControversies with Kalydeco: Newspaper coverage in Canada and the United States of the cystic fibrosis “wonder drug”
Keywords: داروهای یتیم; Kalydeco; Orphan drug; Venture philanthropy; Drug reimbursement; Patient access;
The European patient with Dravet syndrome: Results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome
Keywords: داروهای یتیم; Dravet syndrome; Childhood epilepsy; Antiepileptic drug; Orphan drug; Stiripentol; Clinical trials;
Immunomodulatory activity of orphan drug Elmiron® in female B6C3F1/N mice
Keywords: داروهای یتیم; Immunotoxicity; Orphan drug; Sodium pentosan polysulfate; Interstitial cystitis;
Die Myozyme-Entscheidung des Schweizerischen Bundesgerichts aus der Perspektive des deutschen Verfassungs- und Krankenversicherungsrechts
Keywords: داروهای یتیم; Verteilungsgerechtigkeit; Kosten-Nutzen-Bewertung; Rechtsgleichheit; off-label-use; orphan drug; EvidenzDistributive justice; cost-effectiveness; equal rights; off-label use; orphan drug; evidence-based medicine
Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe
Keywords: داروهای یتیم; Rare lung disease; Orphan drug; Clinical trial design; Outcome measure/biomarker; Registry; Licensing and reimbursement
US biopharmaceutical finance and the sustainability of the biotech business model
Keywords: داروهای یتیم; US biopharmaceutical innovation; R&D finance; Corporate governance; Orphan drug; Stock repurchase; Shareholder value
Rufinamide in children and adults with Lennox–Gastaut syndrome: First Italian multicenter experience
Keywords: داروهای یتیم; Lennox–Gastaut syndrome; Rufinamide; Orphan drug; Pediatrics; Epilepsy; Drop attacks
A comparative study of European rare disease and orphan drug markets
Keywords: داروهای یتیم; Rare disease; Orphan drug; Europe; Health policy; Comparative analysis
The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?
Keywords: داروهای یتیم; Orphan Drug Act; Orphan drug; Healthcare Policy; Blockbuster Drug; Rare disease; Health Technology Assessment
Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: First European experience
Keywords: داروهای یتیم; Rufinamide; Refractory epilepsy; Children; Orphan drug; Partial seizures; Generalized seizures; Lennox–Gastaut syndrome; Dravet syndrome
Les maladies aiguës rares et graves : les oubliées du progrès
Keywords: داروهای یتیم; Maladies rares; Médicaments orphelins; Réanimation; Rare diseases; Orphan drug; Critical care medicine;
Les maladies rares (ou orphelines) : organisation générale de leur prise en charge en 2007
Keywords: داروهای یتیم; Rare disease; Orphanet; Orphan drug; Centre of reference; Maladie rare; Orphanet; Médicament orphelin; Centre de référence;